At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MESO Mesoblast
Not Yet Opened 02-24 16:00:00 EST
16.52
-0.16
-0.96%
盘后16.62
+0.10+0.61%
19:23 EST
High16.55Low16.27Vol165.26K
Open16.30D1 Closing16.68Amplitude1.68%
Mkt Cap2.12BTradable Cap1.30BTotal Shares128.30M
T/O2.72MT/O Rate0.21%Tradable Shares78.65M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Mesoblast Financial Results and Corporate Update Webcast
GlobeNewswire  ·  02-20
Mesoblast Financial Results and Corporate Update Webcast
Mesoblast to Present Half-Year Results as It Expands Global Cell Therapy Portfolio
TIPRANKS  ·  02-20
Mesoblast to Present Half-Year Results as It Expands Global Cell Therapy Portfolio
Mesoblast Touts Ryoncil Survival Data, Prepares Adult SR-aGvHD Pivotal Trial
TIPRANKS  ·  02-12
Mesoblast Touts Ryoncil Survival Data, Prepares Adult SR-aGvHD Pivotal Trial
High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
GlobeNewswire  ·  02-12
High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
Mesoblast Says JPMorgan Chase Becomes Substantial Holder; Shares Rise 6%
MT Newswires Live  ·  02-09
Mesoblast Says JPMorgan Chase Becomes Substantial Holder; Shares Rise 6%
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO) and Mesoblast Limited (OtherMEOBF)
TIPRANKS  ·  01-30
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO) and Mesoblast Limited (OtherMEOBF)
Mesoblast to Start Site Enrollment in Pivotal Trial for Cell Therapy Label Extension; Shares Fall 4%
MT Newswires Live  ·  01-29
Mesoblast to Start Site Enrollment in Pivotal Trial for Cell Therapy Label Extension; Shares Fall 4%
Ryoncil® Net Revenues Increase for the Quarter to US$30M
GlobeNewswire  ·  01-29
Ryoncil® Net Revenues Increase for the Quarter to US$30M
Mesoblast Says 84% Of Patients Completed 28-Day Ryoncil Treatment Regimen In 'Real-World' Clinical Setting
MT Newswires Live  ·  01-27
Mesoblast Says 84% Of Patients Completed 28-Day Ryoncil Treatment Regimen In 'Real-World' Clinical Setting
Mesoblast’s Ryoncil Shows Strong Early Survival in Real-World Use as U.S. Rollout Expands
TIPRANKS  ·  01-27
Mesoblast’s Ryoncil Shows Strong Early Survival in Real-World Use as U.S. Rollout Expands
BRIEF-Mesoblast Says Ryoncil Shows 84% Survival Rate In Children With Sr-Agvhd
Reuters  ·  01-27
BRIEF-Mesoblast Says Ryoncil Shows 84% Survival Rate In Children With Sr-Agvhd
Mesoblast Ltd - Ryoncil Shows 84% Survival Rate in Children With SR-Agvhd
THOMSON REUTERS  ·  01-27
Mesoblast Ltd - Ryoncil Shows 84% Survival Rate in Children With SR-Agvhd
Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
GlobeNewswire  ·  01-27
Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
JPMorgan Ceases to Be Substantial Holder in Mesoblast
TIPRANKS  ·  01-27
JPMorgan Ceases to Be Substantial Holder in Mesoblast
Mesoblast Wins FDA Backing on Pain and Opioid-Reduction Data for Rexlemestrocel-L in Chronic Low Back Pain
TIPRANKS  ·  01-21
Mesoblast Wins FDA Backing on Pain and Opioid-Reduction Data for Rexlemestrocel-L in Chronic Low Back Pain
FDA Signals Support For Mesoblast's Cell Therapy For Chronic Back Pain
Benzinga_recent_news  ·  01-21
FDA Signals Support For Mesoblast's Cell Therapy For Chronic Back Pain
FDA Feedback Boosts Mesoblast’s Rexlemestrocel‑L Bid in Chronic Low Back Pain
TIPRANKS  ·  01-19
FDA Feedback Boosts Mesoblast’s Rexlemestrocel‑L Bid in Chronic Low Back Pain
BRIEF-Mesoblast Says FDA Acknowledges Effects On Pain Intensity Favor Rexlemestrocel-L
Reuters  ·  01-19
BRIEF-Mesoblast Says FDA Acknowledges Effects On Pain Intensity Favor Rexlemestrocel-L
Mesoblast Ltd - Rexlemestrocel-L Receives Rmat Designation From FDA
THOMSON REUTERS  ·  01-19
Mesoblast Ltd - Rexlemestrocel-L Receives Rmat Designation From FDA
Mesoblast Ltd - Significant Pain Reduction and Opioid Cessation in Phase 3 Trial
THOMSON REUTERS  ·  01-19
Mesoblast Ltd - Significant Pain Reduction and Opioid Cessation in Phase 3 Trial

Introduction

Company Name.
Mesoblast
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Issue price:
--